Generics juggernaut Sun Pharma is recalling a specific lot of a chemotherapy drug in the United States due to concerns over glass particle contamination. This action highlights a recurring issue within the pharmaceutical industry, where particulate contamination has increasingly become a focus for regulatory bodies such as the FDA. The recall not only raises questions about the manufacturing processes employed by Sun Pharma but also underscores the broader challenges faced by pharmaceutical companies in maintaining stringent quality control measures.
The implications of this recall are significant for stakeholders across the pharma supply chain. Regulatory professionals must navigate the heightened scrutiny that follows such incidents, while QA/QC teams are tasked with reinforcing protocols to prevent similar occurrences. Furthermore, sourcing and CMC professionals must evaluate their supply chains and manufacturing practices to mitigate risks associated with contamination, ensuring compliance with evolving industry standards.
Use the database as your supply chain compass →
